 Pear Therapeutics Inc NASDAQ: PEAR announced data that further underscore the effectiveness of Somryst for chronic insomnia at the World Sleep 2022. Interim data from the DREAM study, analyzed in mid-Q1 2022, had 991 patients enrolled to date. 